Clinical
RSSArticles
-
Clinical Trials of IL-6 Inhibitors for the Treatment of Neuromyelitis Optica Spectrum Disorders
In a randomized, placebo-controlled trial of neuromyelitis optica spectrum disorder patients, satralizumab monotherapy demonstrated a decrease in relapse rate when compared to placebo. In a randomized, open-label, multicenter trial of tocilizumab vs. azathioprine, treatment with tocilizumab demonstrated a decreased risk of a relapse compared to azathioprine.
-
Study: No Relationship Between Blood Type, COVID-19 Severity
But those with certain blood types may be at higher risk for testing positive.
-
White Paper Calls for Overhaul of Federal Nutrition Research
Coalition of experts say extra funding, better coordination needed to improve public health.
-
Protect the Brain from Air Pollution with … Fish?
Researchers observed better white matter preservation in those who consumed more omega-3 fatty acids.
-
Stroke Risk and Social Determinants of Health
Income levels, health insurance access among several factors researchers connected to incident stroke events.
-
We’d Love to Hear from You!
Please complete our annual reader survey (https://bit.ly/2XYHWdM).
-
The ABCs of CBD: The Fundamentals of Cannabidiol
Cannabidiol (CBD) is one of two major constituents of marijuana and is the non-psychoactive component of cannabis. As its popularity has grown, questions about CBD from patients to their primary care clinicians have increased dramatically. As a patient advocate interpreting the available evidence, the primary care clinician needs to recognize how CBD differs from marijuana, what its clinical utility might be, and what its risks are.
-
We’d Love to Hear from You!
Annual Reader Survey -
Infectious Disease Alert Updates
Metronidazole Neurotoxicity Is Real; 2020 Updated LTBI Treatment Guidelines; Risks of Hookah Smoking
-
A New Treatment for Recurrent Bacterial Vaginosis?
In this randomized controlled trial of 228 women, Lactobacillus crispatus CTV-05 (Lactin-V) applied vaginally for 11 weeks reduced the incidence of recurrent bacterial vaginosis from 45% in the placebo arm to 30% in the Lactin-V arm.